📢Our new paper is out in @ScienceTM 📢
Diabetic retinopathy (DR) is a leading cause of blindness. Patients show vascular changes in their retinas long before vision starts to deteriorate.
What triggers these early defects? Could targeting them prevent vision loss? 🧵
📢Our new paper is out in @ScienceTM 📢
Diabetic retinopathy (DR) is a leading cause of blindness. Patients show vascular changes in their retinas long before vision starts to deteriorate.
What triggers these early defects? Could targeting them prevent vision loss? 🧵
🚨📣The Blood Art Contest winner has been selected! 🎉Congratulations to Alan G. Ramsay and co-authors! @ramsaylab@kingscollegelon
https://t.co/fzanknMEyL #bloodjournals
12 covers have been selected for the 9th Annual Blood Cover Art Contest. Vote now! Voting closes February 7, 2025 and the winner will be announced February 13, 2025. https://t.co/qbU9yiZEqk
🚨MRC-iCASE PhD studentship available🚨to join my lab at @KingsCollegeLon and study lymph node stroma-immune interactions in lung cancer to improve immunotherapy.
🗓️Closing date Tue 29 October 1PM
@KCL_MRCDTP#MRCDTP25#PhDposition#London#AstraZeneca
https://t.co/0PhkhukBus
🚨New paper alert!🚨@LabWhiteford and I are excited to share our latest research published in @BrJPharmacol describing the development and pre-clinical testing 🧪of a novel peptide for neovascular (or wet) age-related macular degeneration (nvAMD).
(Quick 🧵below)
Our review article on the tumor microenvironment in B-cell lymphoma, part of a series collection, is available in Blood. Full access link https://t.co/VL1T5Ok8Kk
@BloodJournal
If you are keen to work as a POSTDOC with us in London on translational cancer research and tumour microenvironment signalling- please apply....5 days left!! https://t.co/WjRiU9FSsa
We are pleased to report our work revealing how ibrutinib enhances anti-cancer T cells, with cover image captured by Despoina! Thanks to group and all our amazing collaborators and funders. (1/2) #Immunotherapy#CLL#lymphoma@NIHFunding @BloodJournal
https://t.co/03QkfjlI3R
Online now:
Read the In The Spotlight Commentary— Structural vulnerabilities in DLBCL for enhanced treatment strategies, by @theLundLab discussing a recent @jclinicalinvest paper, from @RamsayLab.
https://t.co/3czdrPzNMo
Discovering the fibroblastic reticular cell in the immune tumor microenvironment in lymphoma: https://t.co/kGtOTMSuQT
Adam Yuh Lin & @ligordon highlight FRCs as a potential target to optimize immunotherapy for treatment of lymphoma; #Commentary
Related: https://t.co/OswZjHSfaj
It's great to see our funding lead to an interesting #research output from the @RamsayLab. Hopefully future work will build on this to improve treatment options for an aggressive form of lymphoma 👨🔬🩸 @KingsCollegeLon
⬇️⬇️⬇️
https://t.co/JpD4BipKR1